Comparative Pharmacology
Head-to-head clinical analysis: FUSILEV versus METHYLENE BLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUSILEV versus METHYLENE BLUE.
FUSILEV vs METHYLENE BLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FUSILEV (levoleucovorin) is the pharmacologically active isomer of folinic acid. It bypasses dihydrofolate reductase inhibition by dihydrofolate reductase inhibitors (e.g., methotrexate), providing reduced folate that is used in DNA synthesis and repair. It also enhances the efficacy of fluorouracil by stabilizing the ternary complex of thymidylate synthase, thereby inhibiting DNA synthesis.
Methylene blue is a dye that acts as a redox agent, reducing methemoglobin to hemoglobin by activating the enzyme methemoglobin reductase. It also inhibits nitric oxide synthase and guanylate cyclase, causing vasoconstriction in septic shock.
Leucovorin (Fusilev) 200 mg/m2 IV over 2 hours, followed by 5-fluorouracil bolus and infusion, repeated every 2 weeks in combination regimens for advanced colorectal cancer.
1-2 mg/kg IV over 5-30 minutes for methemoglobinemia; repeat after 1 hour if needed. Maximum dose: 7 mg/kg.
None Documented
None Documented
Clinical Note
moderateMethylene blue + Torasemide
"Methylene blue may increase the hypotensive activities of Torasemide."
Clinical Note
moderateMethylene blue + Travoprost
"Methylene blue may increase the hypotensive activities of Travoprost."
Clinical Note
moderateMethylene blue + Unoprostone
"Methylene blue may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateMethylene blue + Hydrochlorothiazide
The terminal elimination half-life of the active metabolite, 5-methyltetrahydrofolate (5-MTHF), is approximately 6-8 hours in healthy adults; clinically, this supports twice-daily or daily dosing schedules.
Terminal elimination half-life approximately 12–24 hours; clinically, levels may persist for 2–3 days due to enterohepatic recycling
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 40-60% of the dose; fecal excretion is negligible.
Renal (80% as leukomethylene blue and unchanged drug); biliary/fecal minor
Category C
Category C
Antidote
Antidote
"Methylene blue may increase the hypotensive activities of Hydrochlorothiazide."